01—Abstract
Summary
Summary of the 10-Q filed November 6, 2024. Cited figures are marked; the original filing is the authoritative source.
Revolution Medicines, Inc. reported its Form 10-Q for the quarter ended September 30, 2024.
The company is a clinical-stage precision oncology company developing RAS(ON) inhibitors and RAS Companion Inhibitors. It has no product revenue; collaboration revenue was zero for the three and nine months ended September 30, 2024, versus $10.8 milliona for the nine months ended September 30, 2023, following the termination of the Sanofi Agreement in June 2023. Net loss was $156.3 million for the quarter and $405.5 million for the nine months, compared with $108.4 million and $274.8 million a year earlier.
Research and development expense rose to $151.8 millionb for the quarter and $404.1 million year to date, driven mainly by RMC-6236 clinical trial costs and headcount growth. As of September 30, 2024, cash, cash equivalents and marketable securities totaled $1.5 billion ($201.3 million in cash and cash equivalents plus $1.35 billion in marketable securities), against an accumulated deficit of $1.5 billion. Management believes existing resources will fund planned operations for at least 12 months following the filing.
The company raised $74.3 millionc net under its at-the-market programs during the nine months, and it established a new $500 million at-the-market program with TD Cowen in August 2024. Management states it will require substantial additional financing for its development programs.
The filing highlights the RASolute 302 Phase 3 registrational trial of RMC-6236 in second-line metastatic pancreatic ductal adenocarcinoma, which is ongoing with an event-driven readout, and plans for a Phase 3 trial in NSCLC expected to start in the first quarter of 2025. Subsequent to quarter end, the company amended its Redwood City lease to add approximately 46,961 square feet at 600 Saginaw Drive, with initial annual base rent of about $3.3 milliond.
02—Key points
Key Highlights
- Zero collaboration revenue for the quarter and nine months ended September 30, 2024, compared with $10.8 million for the nine months ended September 30, 2023, reflecting the June 2023 termination of the Sanofi Agreement.
- Net loss of $156.3 million for the three months and $405.5 million for the nine months ended September 30, 2024, versus $108.4 million and $274.8 million in the prior-year periods.
- Research and development expenses were $151.8 million for the quarter (up $44.0 million) and $404.1 million year to date (up $129.5 million), mainly from RMC-6236 clinical trial expenses and higher headcount.
- Cash, cash equivalents and marketable securities were $1.5 billion at September 30, 2024, and management believes this will fund planned operations for at least 12 months.
- Accumulated deficit reached $1.5 billion; the company states it will require substantial additional financing and has no committed external funding sources.
- A new at-the-market program of up to $500 million with TD Cowen was entered into in August 2024, replacing the 2021 program; $15.3 million in gross proceeds had been raised under it through September 30, 2024.
- The global Phase 3 RASolute 302 trial of RMC-6236 in second-line pancreatic cancer is ongoing, with a readout that is event-driven after full enrollment.
03—One dollar
04—Financials
Financial Highlights
Figures from 10-QQ3 FY2024filed November 6, 2024Financial Statements
Q3 FY2024 against Q3 FY2023
| Line item | Q3 FY2024Q3 FY2023 | Change |
|---|---|---|
| Revenue | $0$0 | — |
| R&D Expenses | $151.75M$107.73M | +40.9% |
| Operating Expenses | $175.71M$123.25M | +42.6% |
| Operating Income | -$175.71M-$123.25M | −42.6% |
| Net Income | -$156.29M-$108.43M | −44.1% |
| EPS (Basic) | $-0.94$-0.99 | +5.1% |
| EPS (Diluted) | $-0.94$-0.99 | +5.1% |
| Shares Outstanding (Basic) | 166.84M109.23M | +52.7% |
| Shares Outstanding (Diluted) | 166.84M109.23M | +52.7% |
05—Questions
Frequently Asked Questions
Does Revolution Medicines have any product revenue?
No. The filing states the company has never generated revenue from product sales and has no products approved for commercial sale. Collaboration revenue was zero for the three and nine months ended September 30, 2024, after the Sanofi Agreement terminated in June 2023.
How much cash does the company have and how long will it last?
As of September 30, 2024, the company had $1.5 billion in cash, cash equivalents and marketable securities. Management believes these resources will fund planned operations for at least 12 months following the date of the 10-Q.
What drove the increase in operating expenses?
Research and development expenses rose $44.0 million (to $151.8 million) in the quarter and $129.5 million (to $404.1 million) for the nine months, primarily from RMC-6236 clinical trial costs, higher salaries from increased headcount, and stock-based compensation. General and administrative expenses also increased, to $24.0 million for the quarter and $69.1 million year to date.
Will the company need to raise more capital?
The filing says the company will require substantial additional financing for its development efforts and has no committed external source of funds. It expects to finance needs through equity or debt offerings, collaborations, licensing or other arrangements, and notes that any equity issuance would dilute existing stockholders.
What are the key clinical milestones disclosed?
The RASolute 302 Phase 3 trial of RMC-6236 in second-line metastatic pancreatic cancer is ongoing, with a readout that is event-driven after full enrollment. The company plans to start a Phase 3 trial of RMC-6236 versus docetaxel in NSCLC, expected in the first quarter of 2025, and expects to disclose updated NSCLC monotherapy data in the fourth quarter of 2024.
06—Continue